Tumor cells produced microvesicles packaged glutaminase 1 (GLS1) via cell division cycle 42 (CDC42) that promoted M2 TAMs polarization and contributed to trastuzumab resistance (Hu et al., 2023). The gene discussed is CDC42; the disease is neoplasm.